瑛泰醫療:二零二三年年報
Shanghai INT Medical Instruments Seeks Listing on Chinese Bourse
Shanghai INT Medical Instruments (HKG:1501) is aiming for a potential listing on a Chinese stock exchange, according to a Friday filing on the Hong Kong bourse. The company on Sunday submitted an appl
Shanghai INT Medical Instruments Submits Application to Shanghai Regulatory Bureau for A Share Listing
Shanghai INT Medical Instruments Submits Application to Shanghai Regulatory Bureau for A Share Listing
Yingtai Healthcare (01501.HK): Submission of listing guidance and filing application materials to the Shanghai Regulatory Bureau of the China Securities Regulatory Commission
Gelonghui, April 7, 丨 Yingtai Medical (01501.HK) announced that on April 7, 2024, the company submitted listing guidance and filing application materials to the Shanghai Regulatory Bureau of the China Securities Regulatory Commission. Due to business development needs, the company plans to prepare for listing on stock exchanges in China (“Recommended A-share listing”). The advising agency for A-share listing is China International Finance Co., Ltd. The proposed A-share listing is still in the early planning stage. As of the announcement date, the company has not submitted any formal listing application to any relevant regulatory authority in China.
Yingtai Healthcare (01501.HK): Issuance of 5 million bonus shares in accordance with the share incentive plan
Gelonghui, April 2, 丨 Yingtai Medical (01501.HK) announced that 5 million bonus shares will be allocated and issued on March 29, 2024 in accordance with the share incentive plan.
This Analyst Just Downgraded Their Shanghai INT Medical Instruments Co., Ltd. (HKG:1501) EPS Forecasts
Today is shaping up negative for Shanghai INT Medical Instruments Co., Ltd. (HKG:1501) shareholders, with the covering analyst delivering a substantial negative revision to this year's forecasts. Re
INT MEDICAL To Go Ex-Dividend On May 30th, 2024 With 0.3 HKD Dividend Per Share
March 19th - $INT MEDICAL(01501.HK)$ is trading ex-dividend on May 30th, 2024. Shareholders of record on May 31st, 2024 will receive 0.3 HKD dividend per share on June 28th, 2024. The ex-dividend
Yingtai Medical (01501) announced annual results, with annual profit of 153 million yuan, an increase of 14.5% over the previous year
Yingtai Healthcare (01501) announced its annual results for the year ended December 31, 2023, with revenue of about 752 million yuan...
INT MEDICAL: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Yingtai Medical (01501) will pay a final dividend of 0.27 yuan per share on June 28
Yingtai Medical (01501) announced that it will be distributed on June 28, 2024 until December 3, 2023...
Yingtai Healthcare (01501) allocates 5 million domestic shares according to the 2023 equity incentive plan
Yingtai Medical (01501) issued an announcement. On March 13, 2024, the company announced the company's stock according to 2023...
Yingtai Medical (01501.HK) held a board meeting on March 18 to approve annual results
Glonghui, March 6, 丨 Yingtai Medical (01501.HK) announced that the company will hold a board meeting on March 18, 2024 (Monday) to approve (among other things) the review of the annual results of the Company and its subsidiaries for publication as of 31 December 2023, and to consider payment of a final dividend (if any).
INT MEDICAL: DATE OF BOARD MEETING
Selected Announcements | Haohai Biotech's annual net profit to mother increased by 130% year-on-year; Zijin Mining's 17.5 billion yuan mine expansion project approved
Huahong Semiconductor: Net profit due to mother decreased by 35.64% year on year in 2023; Times Electric: net profit to mother increased by 21.51% year on year in 2023; BYD Chairman and CEO Wang Chuanfu proposed to repurchase A-shares to 400 million yuan.
Yingtai Medical (01501.HK) plans to buy back a total of 5.0% shares in Shanghai Hanling Medical Devices
Gelonghui Feb. 23丨Yingtai Medical (01501.HK) announced that on February 23, 2024, the company, seller and target company Shanghai Hanling Medical Devices Co., Ltd. signed a repurchase agreement. According to the repurchase agreement, the company agreed to buy back a total of about 5.0% of the target company's shares from the seller. Among them, the company will repurchase about 3.8% of the target company's shares from Waige Yingtai and the company will buy back about 1.2% of the target company's shares from Mr. Ke Wei. After the repurchase is completed, the target company will own approximately 61.36% of the company's equity. Shanghai Han Ling is a non-wholly-owned subsidiary of the company, dedicated to the research and development of products related to heart valves
Shanghai Kindly Medical Instruments Changes Name to Shanghai INT Medical Instrument
Shanghai Kindly Medical Instruments (HKG:1501) has changed its name to Shanghai INT Medical Instruments Co., Ltd. The move came after various regulatory and shareholder approvals were received, a Tues
Kendry Medical (01501.HK) plans to change its name to “Yingtai Medical”
Gelonghui, January 16, 丨 KDL Medical (01501.HK) issued an announcement. Starting at 9:00 a.m. on January 19, 2024, the Chinese stock abbreviation used in H shares trading on the Stock Exchange will be changed from “KDL Medical” to “Yingtai Medical”, and the English language will be changed from “KDL MEDICAL” to “INT MEDICAL”. The company's stock code on the Stock Exchange will remain unchanged as “01501”.
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
Guojin Securities: Sector-suppressing factors, clear pharmaceuticals are expected to welcome a major inflection point in the reversal of economic sentiment
The Zhitong Finance app learned that Guojin Securities released a research report saying that after a long period of decline and adjustment, the pharmaceutical sector ushered in a major inflection point from the second half of 2023 to 2024, and various factors such as policy, performance, and chips bottomed out and reversed.
No Data